The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Thoas Fioretos

Thoas Fioretos

Research team manager

Thoas Fioretos

Clonal conversion of B lymphoid leukemia reveals cross-lineage transfer of malignant states

Author

  • Rajesh Somasundaram
  • Josefine Åhsberg
  • Kazuki Okuyama
  • Jonas Ungerbäck
  • Henrik Lilljebjörn
  • Thoas Fioretos
  • Tobias Strid
  • Mikael Sigvardsson

Summary, in English

Even though leukemia is considered to be confined to one specific hematopoietic cell type, cases of acute leukemia of ambiguous lineage and patients relapsing in phenotypically altered disease suggest that a malignant state may be transferred between lineages. Because B-cell leukemia is associated with mutations in transcription factors of importance for stable preservation of lineage identity, we here investigated the potential lineage plasticity of leukemic cells. We report that primary pro-B leukemia cells from mice carrying heterozygous mutations in either or both the Pax5 and Ebf1 genes, commonly mutated in human leukemia, can be converted into T lineage leukemia cells. Even though the conversion process involved global changes in gene expression and lineage-restricted epigenetic reconfiguration, the malignant phenotype of the cells was preserved, enabling them to expand as T lineage leukemia cells in vivo. Furthermore, while the transformed pro-B cells displayed plasticity toward myeloid lineages, the converted cells failed to cause myeloid leukemia after transplantation. These data provide evidence that a malignant phenotype can be transferred between hematopoietic lineages. This has important implications for modern cancer medicine because lineage targeted treatment of leukemia patients can be predicted to provoke the emergence of phenotypically altered subclones, causing clinical relapse.

Department/s

  • StemTherapy: National Initiative on Stem Cells for Regenerative Therapy
  • Division of Clinical Genetics
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
  • Division of Molecular Hematology (DMH)

Publishing year

2016-11-15

Language

English

Pages

2486-2499

Publication/Series

Genes and Development

Volume

30

Issue

22

Document type

Journal article

Publisher

Cold Spring Harbor Laboratory Press (CSHL)

Topic

  • Cancer and Oncology
  • Medical Genetics

Keywords

  • B-ALL
  • Lineage conversion
  • Transcription factors

Status

Published

ISBN/ISSN/Other

  • ISSN: 0890-9369